EuApproval

AstraZeneca and Daiichi's Innovative Breast Cancer Drug Receives EU Approval

4 months ago

In a significant development for breast cancer treatment, AstraZeneca and Daiichi Sankyo have received endorsement from the European Union for their groundbreaking drug designed to combat one of the most challenging forms of the disease. This approval marks a pivotal moment in the fight against cancer, promising hope to countless patients across Europe.

AstraZeneca's Tagrisso Secures EU Approval for New Lung Cancer Application

5 months ago

AstraZeneca has announced a significant breakthrough in its oncology portfolio as its lung cancer medication, Tagrisso, has received approval from the European Union for an additional indication. This landmark decision allows Tagrisso, which is primarily used to treat non-small cell lung cancer (NSCLC), to be administered for patients with early-stage lung cancer who are at a higher risk of disease recurrence following surgery.

Bayer Secures EU Approval for Heart Drug, Mitigating Patent Worries

6 months ago

Bayer has recently received a significant endorsement from the European Union for its new heart medication, providing the company with much-needed momentum amidst ongoing concerns regarding patent expirations and market competition. This approval is seen as a pivotal moment for Bayer as it works to sustain its market position and boost its pharmaceutical division amidst an evolving landscape.

Novo Nordisk Secures EU Approval for Catalent Plant Acquisition: What It Means for the Pharma Giant

6 months ago

Novo Nordisk has recently achieved a significant milestone in its expansion strategy, as the European Union has granted approval for its acquisition of manufacturing plants from Catalent Inc. This decision marks a pivotal moment for the Danish pharmaceutical powerhouse, which is chiefly renowned for its leadership in diabetes and obesity care solutions.